Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
- 282 Downloads
The clinical and bacteriological efficacy and the tolerability of meropenem versus imipenem/cilastatin (both 1 g t.i.d.) in severe nosocomial infections were compared in a multicentre, randomised, nonblinded study. A total of 151 patients were recruited; 133 (66 meropenem, 67 imipenem/cilastatin) were clinically evaluable and 84 (42 meropenem, 42 imipenem/cilastatin) bacteriologically evaluable. Most clinically evaluable patients (90%) were in intensive care units, required mechanical ventilation (72%), and had received previous antibiotic therapy (62%). The mean (±SD) APACHE II score was 15.2 (±6.6) in the meropenem group and 17.8 (±6.8) in the imipenem/cilastatin group. The primary infections were nosocomial lower respiratory tract infections (56% of patients), intra-abdominal infections (15%), septicaemia (21%), skin/skin structure infections (5%), and complicated urinary tract infections (3%); 35% of the patients had two or more infections. There was no significant difference between the meropenem and imipenem/cilastatin groups in the rates of satisfactory clinical (weighted percentage 87% vs. 74%) or bacteriological (weighted percentage 79% vs. 71%) response. There was a slightly higher rate of clinical success with meropenem against primary or secondary lower respiratory tract infection (89% vs. 76%). Drug-related adverse events occurred in 17% and 15% of meropenem and imipenem/cilastatin patients, respectively. Meropenem (1 g t.i.d.) was as efficacious as the same dose of imipenem/cilastatin in this setting, and both drugs were well tolerated.
KeywordsIntensive Care Unit Mechanical Ventilation Urinary Tract Infection Weighted Percentage Evaluable Patient
Unable to display preview. Download preview PDF.
- 1.Vincent J-L, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin M-H, Wolff M, Spencer RC, Hemmer M, for the EPIC International Advisory Committee: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. Journal of the American Medical Association 1995, 274: 639–644.PubMedGoogle Scholar
- 3.Bax RR Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ: The pharmacokinetics of meropenem in volunteers. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 311–320.Google Scholar
- 4.Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR: Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. European Journal of Clinical Microbiology & Infectious Diseases 1991, 10: 85–88.Google Scholar
- 6.Birnbaum J, Kahan FM, Kropp H, Macdonald S: Carbapenems, a new class of β-lactam antibiotics. Discovery and development of imipenem/cilastatin. American Journal of Medicine 1985, 78, Supplement 6A: 3–21.Google Scholar
- 7.Jones RN, Barry AL, Thornsberry C: In-vitro studies of meropenem. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 9–29.Google Scholar
- 8.Moellering RC, Eliopoulos GM, Sentochnik DE: The carbapenems: new broad spectrum β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 1–7.Google Scholar
- 9.Edwards JR, Turner PJ: Laboratory data which differentiate meropenem and imipenem. Scandinavian Journal of Infectious Diseases 1995, Supplement 96: 5–10.Google Scholar
- 12.National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A4. NCCLS, Villanova, PA, 1990.Google Scholar
- 13.Fleiss JL: Statistical methods for rates and proportions. John Wiley & Sons, New York, 1981, p. 161–165.Google Scholar
- 14.Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken J, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP, and the International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne Dell' Adulto Infection Program: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 1996, 40: 1108–1115.PubMedGoogle Scholar
- 23.Schmutzhard E, Williams KJ, Vukmirovits G, Chmelik V, Pfausler B, Featherstone A, and the Meropenem Meningitis Study Group: A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of meningitis in adults. Journal of Antimicrobial Chemotherapy 1995, 36, Supplement A: 85–98.PubMedGoogle Scholar